Humacyte, Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Humacyte increased authorized common stock from 250M to 550M shares (effective June 9, 2026), and issued a 240,000-share warrant to Mayo Clinic dated May 27, 2026, with exercise price $1.11/share, vesting in three tranches (80,000 each on March 31, 2027, 2028, 2029), contingent on continuation of an Intercompany Services Agreement. The warrant expires May 27, 2031. No dollar consideration amount disclosed for the warrant grant itself.
Why this rating
Stock authorization increase routine for growth-stage biotech. Warrant to Mayo is small (240K shares ~0.04% of authorized post-increase), tied to services agreement, and represents modest dilution. No financing or material transaction disclosed.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.